FGEN
FibroGen Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
Market Cap: 185 Million
Primary Exchange: NASDAQ
Website: http://www.fibrogen.com
Shares Outstanding: 98.8 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 3.11626400947872
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1817 trading days
From: 2018-07-06 To: 2024-03-07
Lowest Point:
FibroGen (FGEN) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-06-12 11:14:53:000
The following slide deck was published by FibroGen, Inc. in conjunction with this Read more … read more...
FibroGen (FGEN) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-06-12 11:14:53:000
The following slide deck was published by FibroGen, Inc. in conjunction with this Read more … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|